Copenhagen, 2014-03-31 09:14 CEST (GLOBE NEWSWIRE) --
Copenhagen, 31 March 2014 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs of its representation in key roles at the Marcus Evans 2014 Discovery Summit, taking place on 31 March - 1 April in Lisbon, Portugal.
Dr. Torsten Hoffmann, Zealand’s Executive Vice President and Chief Scientific Officer will chair the summit, and will give the Chair’s opening address and closing comments. In his address, Dr. Hoffmann will focus on “The significant contribution of pharmaceutical research and development on improving public health and patients’ quality of life.”
Vice President and Head of Research at Zealand, Keld Fosgerau will give a plenary lecture entitled: “Peptide Therapeutics: Current Status and Future Directions,” on 1 April.
Commenting on the summit and Zealand’s role, Dr. Hoffmann states:
“It is a privilege to have been asked to chair this prestigious invitation-only gathering of people in high ranked positions from the world’s leading pharmaceutical and biotech companies. This year’s discussion topic on how to boost preclinical success as a prerequisite to get new and better medicines faster to market for the benefit of patients is of key importance. It is also an area of focused efforts at Zealand, and I look very much forward to leading a stimulating discussion and to sharing ideas with other industry leaders.”
For further information, please contact:
David H. Solomon, President and Chief Executive Officer
Tel: +45 2220 6300
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email: firstname.lastname@example.org
About the Marcus Evans Discovery Summit
The Marcus Evans Discovery Summit is an annual invitation-only gathering of top level decision makers, scientists and strategists from the world’s leading pharmaceutical and biotech companies. With presentations, discussions and networking events, the Summit is one of the foremost events for those in the business of understanding disease mechanism, boosting R&D productivity, identifying targets and understanding the economic and regulatory landscape.
Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead drug invention is lixisenatide, a once-daily prandial GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide (marketed by Sanofi as Lyxumia®) is approved in several countries globally, including Europe and Japan. In the U.S., an NDA is planned to be submitted in 2015, after completion of the ELIXA Cardiovascular outcome study.
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Lilly in diabetes and obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury.
For further information: www.zealandpharma.com
Follow us on Twitter @ZealandPharma
Zealand Pharma A/S
Zealand Pharma A/S Logo